All In Biotech

Drug Trial Radar · NCT06535841

A First-in-Human Safety Trial of MTX-474

MTX-474-S101: A Phase 1 Randomized, Double-Blind, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of MTX-474 in Healthy Adults

Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

78

Actual

Start

Jul 10, 2024

Primary completion

Apr 24, 2025

Study completion Apr 24, 2025

Sponsor

Lead sponsor
Mediar TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-474 administered in healthy adults.

Conditions

  • Healthy

Interventions

  • MTX-474Biological

    MTX-474 is an immunoglobin G1 (IgG1) monoclonal antibody directed against Ephrin B2 that binds to and has demonstrated ability to block phosphorylation of its preferred receptor EphB4. Increased levels of circulating soluble EphrinB2 have been found in patients with systemic sclerosis.

  • PlaceboOther

    Matching Placebo - Normal Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Related Adverse Events in healthy volunteersTime frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)
  2. MTX-474 PK by dose will be evaluated for Cmax, as feasibleTime frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)
  3. Serum sample results will be summarized for presence of Anti-Drug Antibodies during the SAD and MAD portions of the studyTime frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)
  4. MTX-474 PK by dose will be evaluated for AUC0-t, as feasibleTime frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)
  5. MTX-474 PK by dose will be evaluated for AUC0-tau (MAD only), as feasibleTime frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)
  6. MTX-474 PK by dose will be evaluated for AUC0-∞, as feasibleTime frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Herston, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.